GoodRx introduced Employer Direct, a program that allows employers to subsidize manufacturer‑sponsored prices for high‑cost brand drugs — explicitly including GLP‑1 weight‑loss therapies — without adding those medicines to employer health plans, MedCity News reported. The program targets out‑of‑pocket affordability and employer benefit design flexibility. By decoupling subsidies from formal benefits inclusion, the initiative offers employers a lower‑friction route to help employees access costly medications while avoiding insurance‑plan coverage and utilization management. The move will affect employer bargaining, pharmacy benefit manager strategies, and manufacturer patient‑support models. Stakeholders will monitor legal, regulatory, and payor reactions; the program represents a private‑sector response to widening access and affordability pressures for blockbuster branded therapies.